Selection of study endpoints and patients for clinical trials in primary Sjögren's syndrome

Suzanne Arends*, Liseth de Wolff, Liselotte Deroo, Gwenny M Verstappen, Arjan Vissink, Frans G M Kroese, Dirk Elewaut, Isabelle Peene, Hendrika Bootsma

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

4 Citations (Scopus)
71 Downloads (Pure)


In the last decade, many randomised controlled trials (RCTs) with biological DMARDs (bDMARDs) have been performed in patients with primary Sjögren's syndrome (pSS). Unfortunately, no bDMARD has yet been approved for systemic treatment of pSS. The heterogeneity of disease manifestations raises two essential questions: 1) which outcome measure is valid, reliable and responsive to demonstrate treatment efficacy and should be used as primary study endpoint? and 2) which pSS patients should be included in clinical trials? Both the selection of the primary study endpoint and the selection of patients are crucial and evolving issues in clinical trial design in pSS. This article summarises the history and comments the selection of primary study endpoints including the novel development of composite endpoints. Furthermore, this article gives an overview of inclusion criteria used for phase II and III trials, and illustrates by data-analysis based on two prospective observational cohorts that each additional selection criterion will (largely) decrease the number of eligible patients in daily clinical practice.

Original languageEnglish
Pages (from-to)2225-2232
Number of pages8
JournalClinical and Experimental Rheumatology
Issue number12
Early online date26-Oct-2022
Publication statusPublished - Dec-2022

Cite this